R & D

Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

 This material is intended to notify the press release issued on September 16 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.